In 2025, UZC partnered with Roche to develop "NEUROCONNECT" – the first clinically validated neuroscience marketing platform utilizing fMRI and SSVEP to decode subconscious decision-making. Integrated technologies include: 64-channel EEG caps recording prefrontal cortex beta oscillations to calculate Neural Engagement Index (NEI), eye-tracking algorithms measuring amygdala avoidance responses to safety warnings, and AI ethics sandbox rectifying misleading narratives per EMA guidelines. 

During a global Parkinson's drug launch, UZC Zurich Lab proved that 3Hz vertical motion mimicking substantia nigra dopamine rhythms increased patient adherence cognition by 62%; Tokyo's Zen garden metaphors reduced disease-related anxiety by 33%; Buenos Aires team synchronized tango steps with levodopa pharmacokinetics for educational animations. System analyzed 98,000+ neural datasets across 17 countries, establishing the world's first Lancet-endorsed neuroethics framework for pharmaceutical advertising. 

The campaign outperformed prescription targets by 174% with 41% lower misuse risk, winning 2026 Cannes Health Grand Prix and WEF Technology Pioneer Award. Current research at UZC Berlin Ethics Center trains neural plasticity models to predict decade-long brand perception evolution in chronic disease populations.